Ribavirin ante portas: Uptake transporters into hepatocytes dissected

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.

Volume 63, Issue 1, Pages (July 2015)

Volume 46, Issue 3, Pages (March 2007)

Inflammasomes in liver diseases

Volume 61, Issue 4, Pages (October 2014)

Volume 50, Issue 4, Pages (April 2009)

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

Tiny RNA with great effects: miR-155 in alcoholic liver disease

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis.

Immunotherapy of hepatocellular carcinoma

Hepatic CD141+IFNλ+ DC subset: One against all?

Volume 68, Issue 5, Pages (May 2018)

Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR Nicolas Marsollier, Pascal Ferré,

Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar

Reactive oxygen species in the normal and acutely injured liver

Obesity, inflammation, and liver cancer

Matthew T. Kitson, Stuart K. Roberts Journal of Hepatology

Volume 52, Issue 3, Pages (March 2010)

Volume 42, Issue 1, Pages (January 2005)

NS5A inhibitors in the treatment of hepatitis C

Immigration and viral hepatitis

Volume 66, Issue 1, Pages 1-4 (January 2017)

Heidi Barth, Eric Robinet, T. Jake Liang, Thomas F. Baumert

Ype P. de Jong, Charles M. Rice, Alexander Ploss Journal of Hepatology

Allogeneic hematopoietic cell transplant in HCV-infected patients

Living donor liver transplantation: is the hype over?

David G. Bowen, Christopher M. Walker Journal of Hepatology

Volume 59, Issue 4, Pages (October 2013)

Mesenchymal stromal cell therapy for liver diseases

Mechanisms of HBV-related hepatocarcinogenesis

Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection Anaïs Vallet-Pichard,

The place of downstaging for hepatocellular carcinoma

Hepatitis C core protein – The “core” of immune deception?

Volume 61, Issue 1, Pages S108-S119 (November 2014)

Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.

Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel

A dive into the complexity of type I interferon antiviral functions

Volume 61, Issue 1, Pages S69-S78 (November 2014)

Volume 45, Issue 4, Pages (October 2006)

Volume 62, Issue 3, Pages (March 2015)

Darius Moradpour, Arash Grakoui, Michael P. Manns

Autophagy in the liver Journal of Hepatology

Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore

Volume 62, Issue 1, Pages (January 2015)

Host-targeting agents for prevention and treatment of chronic hepatitis C – Perspectives and challenges Mirjam B. Zeisel, Joachim Lupberger, Isabel Fofana,

EASL Clinical Practice Guidelines: Wilson’s disease

Volume 61, Issue 1, Pages S45-S57 (November 2014)

Mona Malz, Federico Pinna, Peter Schirmacher, Kai Breuhahn

Economics of chronic hepatitis B and hepatitis C

Volume 42, Issue 3, Pages (March 2005)

Volume 50, Issue 4, Pages (April 2009)

Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Fei Xiao, Jane A. McKeating, Thomas F. Baumert Journal of Hepatology

Volume 56, Issue 6, Pages (June 2012)

Immigration and viral hepatitis

The potential of induced pluripotent stem cell derived hepatocytes

HCV targeting of patients with cirrhosis

Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential rather than concomitant administration with pegylated interferon and ribavirin? Lawrence.

Volume 63, Issue 1, Pages (July 2015)

Volume 51, Issue 2, Pages (August 2009)

HCV animal models and liver disease

Pathogenesis of cholestatic hepatitis C

Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing Roongruedee Chaiteerakij,

Chimeric mouse model of hepatitis B virus infection

Eric Robinet, Thomas F. Baumert Journal of Hepatology

Volume 62, Issue 5, Pages (May 2015)

Reversion of disease manifestations after HCV eradication

Presentation transcript:

Ribavirin ante portas: Uptake transporters into hepatocytes dissected Bertram Bengsch, Robert Thimme Journal of Hepatology Volume 52, Issue 4, Pages 469-471 (April 2010) DOI: 10.1016/j.jhep.2009.12.019 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 1 The putative antiviral mechanisms of action of Ribavirin during the treatment of HCV infection. Upon Ribavirin uptake into hepatocytes through the ENT1 transporter, it gets modified by cellular kinases to RMP and RTP. RTP causes enhanced HCV mutagenesis due to erroneous integration of RTP into newly synthesized viral RNA and may also directly inhibit HCV replication. RMP inhibits IMPDH which converts IMP to GTP, thus effectively depleting the intracellular GTP pool required for viral replication. In addition, Ribavirin treatment may enhance the antiviral T cell function. TH, T helper cells; RdRp, RNA-dependent RNA polymerase. Journal of Hepatology 2010 52, 469-471DOI: (10.1016/j.jhep.2009.12.019) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions